DailyIQ
Last updatedUpdating…

NVO·Novo Nordisk A/S

$38.13
+0.07 (+0.18%)
After Hours
High
$38.42
Open
$37.92
Market Cap
167.96B
52W High
$64.35
Low
$37.70
P. Close
$38.13
P/E
9.76
52W Low
$35.06
Fwd P/E
11.49
DailyIQ Est.
$44.97
Inst. Ownership
2.3%
Short Interest
0.72%
Days to Cover
1.7
Div. Yield
4.87%
Next Ex-Div
~Feb 15
Div. Growth
7+ yrs
Technical Score (1D)
14
BEARISH
News Sentiment
38
BEARISH
On Oct 13, Novo Nordisk closed at $38.06, falling 1.35 % and lagging the S&P 500 and Nasdaq. The company’s upcoming earnings were projected to show a 20.59 % year‑over‑year decline in earnings per share and a 3.03 % drop in quarterly revenue. Analysts noted that full‑year consensus estimates also reflected modest declines in earnings and revenue. Investors were monitoring the company’s guidance revisions as the market reacted to the weaker outlook. The report highlighted that the stock’s decline was tied to the projected earnings and revenue downturns.
LOW TARGET
$40 +3.7%
4 analysts
MEAN TARGET
$45 +18.7%
20 analysts
HIGH TARGET
$61 +61.2%
12 analysts
PRICE RANGE
$39.53 - $61.45
SB / B / H / S / SS
5/6/22/2/1
DAILYIQ EST.
$44.97 (+18.0%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYQ
Country
Denmark
Symbol
NVO
Description
Novo Nordisk A/S is a global pharmaceutical company specializing in treatments for diabetes, obesity, and rare diseases. Its core business centers on developing, manufacturing, and distributing a portfolio of medications, including insulin pens, growth hormone pens, and injection needles, catering to diverse patient needs across multiple international markets. The company's value proposition lies in its dedication to innovation, as evidenced by its smart diabetes solutions like smart insulin pens and dose guidance applications, alongside its focus on emerging therapies. Novo Nordisk operates through two primary segments: Diabetes and Obesity Care, and Rare Disease, addressing significant unmet medical needs. Strategic collaborations, such as the agreement with UNICEF, further demonstrate the company's commitment to improving global health outcomes.
Earnings Summary
Novo Nordisk A/S is a global pharmaceutical company specializing in diabetes, obesity, and rare disease treatments, operating through its Diabetes and Obesity Care and Rare Disease segments and leveraging smart diabetes solutions and strategic collaborations such as with UNICEF. In the most recent two quarters, Q1 2025 and Q2 2025, the company posted EPS of $6.53 and $5.96 respectively, slightly below the $6.115 and $6.00433 estimates for Q4 2024 and Q1 2025, indicating a modest EPS slowdown, while revenue fell from $85.683bn in Q4 2024 to $76.857bn in Q2 2025, a 10.6% decline, and further to $74.976bn in Q3 2025, reflecting a continued revenue contraction. The company beat estimates in Q4 2024 and Q1 2025 but missed in Q2 2025, showing an inconsistent pattern of earnings performance. Historically, Novo Nordisk has delivered YoY revenue growth in the high 20% range for several years, with recent quarters showing a reversal to negative growth, yet it has maintained a track record of beating EPS estimates in 3 of the last 4 quarters, underscoring resilience in profitability. Recent news highlights a projected 20.59% YoY EPS decline and a 3.03% revenue drop for the upcoming quarter, which may explain the market’s cautious stance and the 11.21% share decline over the past month; these developments suggest investors are closely monitoring guidance revisions amid a broader earnings downturn.

EPS

EstBeatMiss
$3.84$4.72$5.60$6.49$7.37Q4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$6.96 - -
Q3'25$4.24$4.50+6.0%
Q2'25$6.00$5.96-0.7%
Q1'25$6.07$6.53+7.5%
Q4'24$6.12$6.34+3.7%

Revenue

EstBeatMiss
$69.4B$74.0B$78.6B$83.2B$87.8BQ4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$71.6B - -
Q3'25 - $75.0B -
Q2'25 - $76.9B -
Q1'25 - $78.1B -
Q4'24 - $85.7B -

Market Data

NVO Stock Snapshot

BEARISH14/100
$37.98−$0.15 (0.4%)
Market cap
167.96B
P/E ratio
9.8
Day range
$37.70 – $38.42
News sentiment
38/100 · Bearish
Analyst target
$45.25 (+19.1%)
Consensus
Hold · 36 analysts
52-week range+8.3% off low · -41.0% from high
$35.06$64.35
Price $37.98 DailyIQ Est. $44.97

Price action on NVO is defensive - rallies are being sold rather than extended. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What NVO's own history says about today's numbers

Realized volatility (21d)
35.2% 77th pct
Below its peak
-74.3%
vs 200-day average
-16.0%
Up days (1y)
45%

Novo Nordisk A/S is currently running 35.2% annualised volatility over the last 21 sessions. Measured against NVO's own 13 years of daily returns rather than a market-wide average, that is the 77th percentile — elevated for this stock, against a typical reading of 26.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

NVO is trading -74.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.0%, and the deepest was -50.4% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -16.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 15th percentile — a narrower gap than it typically runs. Over the past year NVO closed higher on 45% of sessions, and it is currently 3 sessions into a falling streak.

On October specifically: over 14 years of records, NVO finished the month higher 6 of 14 times, with a median return of -1.6% and an average of -1.3%. Its strongest month historically has been April at +3.5% on average, its weakest September at -3.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: NVO has opened more than 2% away from the prior close in 249 of 3,268 sessions (7.6% of the time), with the largest gaps running +6.5% and -14.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against NVO's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of NVO's sector?

Novo Nordisk A/S sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Pharmaceuticals industry group, NVO ranks 12th of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#12 of 15

Options Market

What is the options market pricing for NVO?

CallsPuts

For Novo Nordisk A/S's nearest expiry (2026-10-16, 2 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.89), with at-the-money implied volatility around 31.1%. The options market is pricing roughly a ±2.2% move by that expiry — a range of about $37.22–$38.88.

Put/call ratio (2026-10-16)
0.89
ATM implied volatility
31.1%
Total open interest
141,116
Expected move by 2026-10-16
±2.2% ($37.22–$38.88)

Analyst Rating Changes

Are analysts turning bullish or bearish on NVO?

BMO Capital most recently reiterated its rating on Novo Nordisk A/S to Market Perform on Oct 12, 2026 with a price target of $40 (from $47). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
BMO Capital — Market Perform
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Oct 12, 2026BMO CapitalMaintainedMarket Perform$47 → $40
Sep 11, 2026Morgan StanleyDowngradeEqual-Weight → Underweight$40
Mar 2, 2026Goldman SachsDowngradeBuy → Neutral$63 → $41
Feb 24, 2026JP MorganDowngradeOverweight → Neutral-
Jan 9, 2026CICCInitiatedOutperform$74
Dec 8, 2025Argus ResearchDowngradeBuy → Hold-
Nov 28, 2025Goldman SachsMaintainedBuy$60 → $54
Nov 25, 2025BMO CapitalMaintainedMarket Perform$50 → $46
Nov 24, 2025HSBCDowngradeBuy → Hold-
Oct 14, 2025BMO CapitalMaintainedMarket Perform$50 → $55
Oct 2, 2025HSBCUpgradeHold → Buy$70
Sep 29, 2025Morgan StanleyDowngradeEqual-Weight → Underweight$59 → $47

Peers & ETF holders

NVO peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

38/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Novo Nordisk closed at $38.06 on Oct. 13, falling 1.35% and lagging broader indices. The company’s upcoming earnings were projected to show a 20.59% year‑over‑year decline in EPS and a 3.03% drop in quarterly revenue. Analysts noted that the consensus estimates for the full year also reflected modest declines in earnings and revenue. Investors are monitoring the company’s guidance revisions as the market reacts to the weaker outlook.
What did this article say?
BMO Capital’s analyst Evan David Seigerman downgraded Novo Nordisk to a Market Perform rating and reduced the price target from $47 to $40. The adjustment reflects concerns over the company’s earnings outlook and competitive pressures in the diabetes market. The downgrade signals a modest negative outlook for the stock, potentially impacting investor sentiment.
What did this article say?
On 6 May 2026, Novo Nordisk announced the start of a share repurchase programme under MAR regulations. The programme is part of a larger 12‑month plan to buy back up to DKK 15 billion of shares. The move signals confidence in the company’s financial strength and is expected to support the share price. It reflects a strategic use of excess cash rather than a change in core operations. The announcement was made in Denmark and complied with European regulatory requirements.
What did this article say?
The article compares Novo Nordisk (NVO) and Bristol Myers Squibb (BMY) as potential 2026 investments, highlighting each company’s core therapeutic focus and market position. Novo Nordisk is noted for its dominance in obesity and diabetes, while BMY is described as a diversified biopharma leader in oncology and hematology. Both firms face evolving regulatory environments, and the piece emphasizes the need for data‑driven valuation analysis. No specific earnings guidance or material corporate actions for NVO are disclosed, leaving the outlook neutral. The comparison serves as a framework for investors weighing growth versus stability.
What did this article say?
Novo Nordisk (NVO) increased its full‑year revenue outlook, signaling confidence in future growth. The company also outlined a strategy to achieve peer‑level revenue expansion through 2030. Despite the optimistic guidance, market participants reacted negatively, citing pricing headwinds and concerns over the pace of new product uptake. The announcement highlighted the company’s ongoing efforts to sustain its obesity and diabetes portfolio, including the recent launch of a Wegovy pill. Overall, the guidance upgrade was viewed as a modest positive catalyst tempered by lingering market skepticism.
What did this article say?
Citi Research reduced its price target for Novo Nordisk (NVO) to DKK 296 from DKK 310, citing limited margin expansion prospects through 2030. The downgrade followed the company’s Capital Markets Day, where management indicated operating margins would remain broadly stable. Citi also lowered its earnings forecasts for 2028‑2030 by 2‑4% and trimmed the valuation multiple to 14x earnings. The bank maintained a neutral rating, reflecting a cautious outlook on future profitability.
What did this article say?
Novo Nordisk reported a U.S. FDA review update for its haemophilia A therapy denecimig, addressing manufacturing feedback. The company also presented new CagriSema data on brain and metabolic effects in obesity and diabetes at the EASD conference, alongside real‑world evidence comparing semaglutide and tirzepatide. These developments provide incremental progress in the company’s therapeutic pipeline but do not represent a major catalyst. The updates suggest steady advancement without significant upside or downside impact.
What did this article say?
Novo Nordisk reported historically strong earnings, prompting investors to question why the share price had not yet reflected the performance. In a recent interview, the CEO explained that market pricing often lags behind corporate results, citing a time‑difference effect. The company’s financials remained solid, but the stock’s delayed reaction suggests a mild, short‑term headwind rather than a fundamental shift.

Technical Analysis

Real-time indicators across multiple timeframes

14
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $4.91B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Loomis Sayles & Co L P▲ Buy18,594,3520.42%$891.41M2026-08-14
Morgan Stanley▲ Buy11,659,8690.26%$558.97M2026-08-13
Bank of America Corp▲ Buy11,176,7120.25%$535.81M2026-08-14
Goldman Sachs Group Inc▲ Buy9,180,4900.21%$440.11M2026-08-14
Fisher Asset Management, LLC▼ Sell8,324,9480.19%$399.10M2026-08-04
Capital World Investors▼ Sell5,205,9260.12%$249.61M2026-08-12
Susquehanna International Group, LLP▼ Sell4,815,5760.11%$230.86M2026-08-14
Wells Fargo & Company▲ Buy4,657,6420.11%$223.29M2026-08-14
BlackRock, Inc.▲ Buy3,861,1820.09%$185.11M2026-08-07
Northern Trust Corp▲ Buy3,693,1980.08%$177.05M2026-08-13
Renaissance Technologies LLC▼ Sell3,032,4210.07%$145.37M2026-08-13
Farallon Capital Management LLC▲ Buy2,619,0000.06%$125.55M2026-08-14
FMR LLC (Fidelity)▲ Buy2,306,3930.05%$110.57M2026-08-13
Millennium Management LLC▲ Buy2,035,9390.05%$97.60M2026-08-14
Marshall Wace, LLP▼ Sell1,707,1040.04%$81.84M2026-08-13
Maverick Capital Ltd▼ Sell1,653,8720.04%$79.29M2026-08-14
JPMorgan Chase & Co▼ Sell1,612,4260.04%$77.94M2026-08-12
Citadel Advisors LLC▼ Sell1,366,2750.03%$65.50M2026-09-02
Balyasny Asset Management L.P.▲ Buy1,109,9820.03%$53.21M2026-08-14
Citigroup Inc▼ Sell1,006,0320.02%$48.23M2026-08-03
Adage Capital Partners GP, L.L.C.▲ Buy877,6350.02%$42.07M2026-08-14
D. E. Shaw & Co., Inc.▼ Sell697,5670.02%$33.44M2026-08-14
Invesco Ltd.▼ Sell686,1210.02%$32.89M2026-08-14
AQR Capital Management LLC▲ Buy324,1490.01%$15.54M2026-08-14
ExodusPoint Capital Management, LP▼ Sell170,6520.00%$8.18M2026-08-14
Q2 2026 flow:13.49M sh bought ($646.60M)13.87M sh sold ($665.62M)net -386.7K sh (−$19.02M)
Congressional Trading Activity
22 disclosed trades · ~$274.0K est. traded value · 12 buys, 10 sells
MemberChamberStateTypeAmountTradedFiled
Kevin HernHouseOK01▼ Sell$1K - $15K2026-09-102026-09-25
Kevin HernHouseOK01▼ Sell$1K - $15K2026-08-312026-09-25
Scott Scott FranklinHouseFL18▲ Buy$1K - $15K2026-08-262026-09-17
Alan ArmstrongSenateOK▲ Buy$15K - $50K2026-03-302026-07-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-10-152025-10-20
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-09-112025-10-22
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-08-282025-08-29
Marjorie Taylor GreeneHouseGA14▲ Buy$15K - $50K2025-08-192025-08-20
Scott Scott FranklinHouseFL18▲ Buy$15K - $50K2025-08-042025-08-14
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-08-042025-09-12
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-102025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-092025-08-13
Laurel LeeHouseFL15▼ Sell$1K - $15K2025-05-082025-06-22
Scott Scott FranklinHouseFL18▲ Buy$1K - $15K2025-03-272025-04-11
Byron DonaldsHouseFL19▼ Sell$1K - $15K2025-03-202025-04-14
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12
Tommy TubervilleSenateAL▼ Sell$15K - $50K2024-01-192024-02-14
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2019-03-112019-04-17
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2017-09-082017-10-06